Form 144 Enliven Therapeutics For: 30 April
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Enliven Therapeutics Inc (ELVN)
Enliven Therapeutics Inc stock price live, this page displays NASDAQ ELVN stock exchange data. View the ELVN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Enliven Therapeutics Inc real time stock price chart below.
What Is the Enliven Therapeutics Inc Stock Price Today?
The Enliven Therapeutics Inc stock price today is 41.670.
What Is the Stock Symbol for Enliven Therapeutics Inc?
The stock symbol for Enliven Therapeutics Inc is "ELVN."
What Stock Exchange Does Enliven Therapeutics Inc Trade On?
Enliven Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Enliven Therapeutics Inc a Good Stock to Buy?
Determining whether Enliven Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ELVN quote. (ISIN: US29337E1029) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
What Is the Enliven Therapeutics Inc Stock Price Today?
The Enliven Therapeutics Inc stock price today is 41.670.
What Is the Stock Symbol for Enliven Therapeutics Inc?
The stock symbol for Enliven Therapeutics Inc is "ELVN."
What Stock Exchange Does Enliven Therapeutics Inc Trade On?
Enliven Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Enliven Therapeutics Inc a Good Stock to Buy?
Determining whether Enliven Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ELVN quote. (ISIN: US29337E1029) Test %CURRENT_YEAR% | %DIVIDEND_YIELD% | %UPSIDE_OR_DOWNSIDE%
NASDAQ
Currency in USD
Fair Value
An estimate of a Enliven Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
40.060
43.570
52 wk Range
14.785
48.530
ELVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Enliven Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
40.06043.570
52 wk Range
14.78548.530
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ELVN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Enliven Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
51.286
Upside
+23.08%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Imara Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Imara Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Form 144 Enliven Therapeutics For: 30 April
- Investing.com
- Imara Inc receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form PRE 14A Enliven Therapeutics For: 15 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 51.286
(+23.08% Upside)
Earnings
Latest Release
Mar 03, 2026
EPS / Forecast
-0.48 / -0.46
Revenue / Forecast
-- / 8.33K
Compare ELVN to Peers and Sector
Metrics to compare | ELVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −24.2x | −0.5x | −0.5x | |
PEG Ratio | −7.34 | 0.00 | 0.00 | |
Price/Book | 5.5x | 2.1x | 2.6x | |
Price / LTM Sales | - | 2.1x | 3.2x | |
Upside (Analyst Target) | 26.1% | 74.4% | 48.8% | |
Fair Value Upside | Unlock | 34.1% | 6.9% | Unlock |
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Enliven Therapeutics (ELVN) Stock Price Today?
The Enliven Therapeutics stock price today is 41.670 USD.
What Stock Exchange Does Enliven Therapeutics Trade On?
Enliven Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Enliven Therapeutics?
The stock symbol for Enliven Therapeutics is "ELVN."
What Is the Enliven Therapeutics (ELVN) Afterhours Price Today? (Afterhours variable test: 42.500) Current Date: May 01, 2026
After hours price: 42.500. After hours price change (units): 0.800. Price change percentage: 1.920%
What Is the Enliven Therapeutics Market Cap?
As of today, Enliven Therapeutics market cap is 2.500B USD.
What Is Enliven Therapeutics's Earnings Per Share (TTM)?
The Enliven Therapeutics EPS (TTM) is -1.830.
When Is the Next Enliven Therapeutics Earnings Date?
Enliven Therapeutics will release its next earnings report on May 20, 2026.
From a Technical Analysis Perspective, Is ELVN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Enliven Therapeutics Stock Split?
Enliven Therapeutics has split 1 times.
How Many Employees Does Enliven Therapeutics Have?
Enliven Therapeutics has 60 employees.
What is the current trading status of Enliven Therapeutics (ELVN)?
As of May 01, 2026, Enliven Therapeutics (ELVN) is trading at a price of 41.670 USD, with a previous close of 41.230 USD. The stock has fluctuated within a day range of 40.060 USD to 43.570 USD, while its 52-week range spans from 14.785 USD to 48.530 USD.
What Is Enliven Therapeutics (ELVN) Price Target According to Analysts?
The average 12-month price target for Enliven Therapeutics is 51.286 USD, with a high estimate of 60 USD and a low estimate of 41 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +23.08% Upside potential.
What Is the ELVN Premarket Price?
ELVN's last pre-market stock price is 41.240 USD. The pre-market share volume is 3,960.000, and the stock has decreased by 0.010, or 0.020%.
What Is the ELVN After Hours Price?
ELVN's last after hours stock price is 42.500 USD, the stock has decreased by 0.800, or 1.920%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.